Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/2705
Title: Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases
Authors: Teachey, D. T.
Finklestein, J. Z.
Ebb, D. H.
Whitehead, B.
Jacobs, B.
Siegel, D. M.
Keen, R.
Hsiao, E.
Pignolo, R. J.
Kaplan, F. S.
Andolina, J. R.
Adamson, P. C.
Issue Date: 2018
Source: 109 , 2018, p. 276-280
Pages: 276-280
Journal: Bone
Abstract: Background: Fibrodysplasia ossificans progressiva (FOP) is an ultrarare genetic disorder of progressive, disabling heterotopic ossification (HO) for which there is presently no definitive treatment. Research studies have identified multiple potential targets for therapy in FOP, and novel drug candidates are being developed for testing in clinical trials. A complementary approach seeks to identify approved drugs that could be re-purposed for off-label use against defined targets in FOP. One such drug is imatinib mesylate, a tyrosine kinase inhibitor originally developed for use in patients with chronic myeloid leukemia (CML). Imatinib has the desirable effect of attacking multiple targets involved in the early hypoxic and inflammatory stages of FOP flare-ups, including HIF1-α PDGFRα c-KIT, and multiple MAP kinases. Results: Based on compelling biologic rationale, strong preclinical data, and a favorable safety profile, imatinib has been prescribed on an off-label basis in a non-trial setting in seven children with continuous FOP flare-ups, predominantly in the axial regions, and which were not responsive to standard-of-care regimens. Anecdotal reports in these seven isolated cases document that the medication was well-tolerated with a ubiquitous reported decrease in the intensity of flare-ups in the six children who took the medication. Conclusions: These early clinical observations support the implementation of clinical trials in children with uncontrolled FOP flare-ups to determine if imatinib may ameliorate symptoms or alter the natural history of this debilitating and life-threatening disease.L6175326142017-08-01
2018-11-23
DOI: 10.1016/j.bone.2017.07.019
Resources: https://www.embase.com/search/results?subaction=viewrecord&id=L617532614&from=exporthttp://dx.doi.org/10.1016/j.bone.2017.07.019 |
Keywords: treatment response;preschool child;bisphosphonic acid derivativecorticosteroid;imatinib;nonsteroid antiinflammatory agent;palovarotene;prednisone;abdominal discomfort;article;child;clinical article;disease course;drug dose increase;drug efficacy;drug safety;female;fibrodysplasia ossificans progressiva;health care system;human;loose feces;male;off label drug use;ossifying myositis;prescription;prospective study;school child
Type: Article
Appears in Sites:Children's Health Queensland Publications

Show full item record

Page view(s)

70
checked on Mar 20, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.